ATYR aTyr: Forward P/S Multiple
The upgrade of the laboratory base to expand clinical testing triggered growth, and the expected P/S ratio captured this momentum, with the current mark equal to 78.50. aTyr Pharma, Inc. (ATYR) is mitigating downtime risks by engaging external CDMO partners for protein synthesis. Further success depends on financial stability and the confirmation of safety for the therapy targeting rare lung pathologies.
Comprehensive metric breakdowns and analytics for aTyr Pharmaceuticals (ATYR)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Debt to Equity aTyr Pharma, Inc.|ATYR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio aTyr Pharma, Inc.|ATYR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio aTyr Pharmaceuticals|ATYR - Long-Term Liabilities|Company Short-Term Debts aTyr Pharma|Quick Ratio atyrpharma.com
- net income and valuation multiples indicators:
ATYR - Net Profit|Expected Profit aTyr Pharma, Inc.|ATYR - Company Value to Net Income|Future Price to Earnings aTyr|ATYR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple aTyr Pharmaceuticals|ATYR - Operating profit EBITDA|Net earnings per share for the last 12 months aTyr Pharma|ATYR - Earnings per share for the trailing year|Quarterly EPS earnings growth atyrpharma.com|ATYR - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year aTyr Pharma, Inc.
- issuer revenue and sales details:
Summary company analysis:ATYR (aTyr Pharma)
The forward P/S ratio is used to assess the market value of aTyr Pharma, Inc. (ATYR), which is developing innovative tRNA therapy with efzofitimod. This chart compares current market capitalization with expected revenue, separating the fundamental trend from market noise and currency volatility; this allows investors to determine a fair share price relative to future cash flows from the drug's commercialization.
Direct competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX (Protagonist Therapeutics) - Forward Price-to-Revenue Multiple|IMVT: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple KNSA|Market Cap to Future Revenue Ratio Grifols SA GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Forward Price to Sales|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales BCRX|VERA - Price-to-Projected Revenue Ratio|Future Price to Revenue DNTH|PHVS: Forward P/S Multiple|AbCellera Corp - Forward Price to Sales|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Forward P/S Multiple precigen.com|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO - Forward Price-to-Revenue Multiple|Immunome, Inc. - Forward P/S Multiple|GOSS - Forward P/S Multiple|KALV (KalVista Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|Septerna, Inc. - Forward Price to Sales|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Savara Pharma (SVRA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Market Cap to Projected Revenue|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|ENGN - Forward Price-to-Revenue Multiple|RAPT: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aerovate Therapeutics Inc JBIO|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TLSA|CABA (Cabaletta Bio Inc.) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Bio)|THTX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Future Price to Revenue CLYM|ZURA: Forward P/S Multiple|Adagene Inc. - Forward Price to Sales|IMA (ImageneBio) - Forward P/S Multiple|Forward P/S Multiple Shattuck Therapeutics|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|CNTB (connectbiopharm.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA - Forward Price-to-Revenue Multiple|InflaRx GmbH - Forward P/S Multiple|XFOR - Forward P/S Multiple|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity - Forward Price to Sales|INMB (INmune Bio Corp) - Forward P/S Multiple|Barinthus Biotherapeutics Corp (BRNS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Forward Price-to-Revenue Multiple|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue IBIO|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|Forward P/S Multiple BOLT|Forward P/S Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AIM (AIM ImmunoTech, Inc.)|ADTX: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Vyome Therapeutics - Forward Price to Sales|Forward Price-to-Revenue Multiple REVB|INDP: Forward Price to Sales|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI: Future Price to Revenue|Forward P/S Multiple AFMD (Affimed N.V.)|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|IGMS - Forward P/S Multiple|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Ocean Biomedical Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
